BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 32483596)

  • 1. Is Next-Generation Sequencing Alone Sufficient to Reliably Diagnose Gliomas?
    Kam KL; Appin CL; Mao Q; Ikegami S; Lukas RV; Nikiforova MN; Roy S; Brat DJ; Horbinski C
    J Neuropathol Exp Neurol; 2020 Jul; 79(7):763-766. PubMed ID: 32483596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical evaluation of a dedicated next generation sequencing panel for routine glioma diagnostics.
    Synhaeve NE; van den Bent MJ; French PJ; Dinjens WNM; Atmodimedjo PN; Kros JM; Verdijk R; Dirven CMF; Dubbink HJ
    Acta Neuropathol Commun; 2018 Nov; 6(1):126. PubMed ID: 30470264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Next-Generation Sequencing in Molecular Subtyping of Lower-Grade Diffuse Gliomas: Application of the World Health Organization's 2016 Revised Criteria for Central Nervous System Tumors.
    Carter JH; McNulty SN; Cimino PJ; Cottrell CE; Heusel JW; Vigh-Conrad KA; Duncavage EJ
    J Mol Diagn; 2017 Mar; 19(2):328-337. PubMed ID: 28042970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.
    Dubbink HJ; Atmodimedjo PN; Kros JM; French PJ; Sanson M; Idbaih A; Wesseling P; Enting R; Spliet W; Tijssen C; Dinjens WN; Gorlia T; van den Bent MJ
    Neuro Oncol; 2016 Mar; 18(3):388-400. PubMed ID: 26354927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrating a Large Next-Generation Sequencing Panel into the Clinical Diagnosis of Gliomas Provides a Comprehensive Platform for Classification from FFPE Tissue or Smear Preparations.
    Parilla M; Kadri S; Patil SA; Fitzpatrick C; Ritterhouse L; Segal J; Collins J; Pytel P
    J Neuropathol Exp Neurol; 2019 Mar; 78(3):257-267. PubMed ID: 30698790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted next-generation sequencing panel (TruSight Tumor 170) in diffuse glioma: a single institutional experience of 135 cases.
    Na K; Kim HS; Shim HS; Chang JH; Kang SG; Kim SH
    J Neurooncol; 2019 May; 142(3):445-454. PubMed ID: 30710203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic Detection of Allelic Losses and Imbalances by Next-Generation Sequencing: 1p/19q Co-Deletion Analysis of Gliomas.
    Dubbink HJ; Atmodimedjo PN; van Marion R; Krol NMG; Riegman PHJ; Kros JM; van den Bent MJ; Dinjens WNM
    J Mol Diagn; 2016 Sep; 18(5):775-786. PubMed ID: 27461031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diffuse Gliomas for Nonneuropathologists: The New Integrated Molecular Diagnostics.
    Lee SC
    Arch Pathol Lab Med; 2018 Jul; 142(7):804-814. PubMed ID: 29775073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early experience with formalin-fixed paraffin-embedded (FFPE) based commercial clinical genomic profiling of gliomas-robust and informative with caveats.
    Movassaghi M; Shabihkhani M; Hojat SA; Williams RR; Chung LK; Im K; Lucey GM; Wei B; Mareninov S; Wang MW; Ng DW; Tashjian RS; Magaki S; Perez-Rosendahl M; Yang I; Khanlou N; Vinters HV; Liau LM; Nghiemphu PL; Lai A; Cloughesy TF; Yong WH
    Exp Mol Pathol; 2017 Aug; 103(1):87-93. PubMed ID: 28663030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A tailored next-generation sequencing panel identified distinct subtypes of wildtype IDH and TERT promoter glioblastomas.
    Higa N; Akahane T; Yokoyama S; Yonezawa H; Uchida H; Takajo T; Kirishima M; Hamada T; Matsuo K; Fujio S; Hanada T; Hosoyama H; Yonenaga M; Sakamoto A; Hiraki T; Tanimoto A; Yoshimoto K
    Cancer Sci; 2020 Oct; 111(10):3902-3911. PubMed ID: 32748499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adult Diffuse Astrocytic and Oligodendroglial Tumors.
    Gestrich CK; Couce ME; Cohen ML
    Neurosurgery; 2021 Oct; 89(5):737-749. PubMed ID: 33611566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy.
    Kline CN; Joseph NM; Grenert JP; van Ziffle J; Talevich E; Onodera C; Aboian M; Cha S; Raleigh DR; Braunstein S; Torkildson J; Samuel D; Bloomer M; Campomanes AGA; Banerjee A; Butowski N; Raffel C; Tihan T; Bollen AW; Phillips JJ; Korn WM; Yeh I; Bastian BC; Gupta N; Mueller S; Perry A; Nicolaides T; Solomon DA
    Neuro Oncol; 2017 May; 19(5):699-709. PubMed ID: 28453743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic analysis to complement histopathological diagnosis of brain tumors.
    Nakamura M; Shimada K; Ishida E; Nakase H; Konishi N
    Histol Histopathol; 2007 Mar; 22(3):327-35. PubMed ID: 17163407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ATM mutations improve radio-sensitivity in wild-type isocitrate dehydrogenase-associated high-grade glioma: retrospective analysis using next-generation sequencing data.
    Kim N; Kim SH; Kang SG; Moon JH; Cho J; Suh CO; In Yoon H; Chang JH
    Radiat Oncol; 2020 Jul; 15(1):184. PubMed ID: 32736562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic Utility of Oncomine Comprehensive Assay v3 in Differentiating Between Isocitrate Dehydrogenase (IDH)-mutated Grade II-III Astrocytoma and Oligodendroglioma.
    Kim SW; Park BJ; Kim HS; Na K
    In Vivo; 2021; 35(2):921-927. PubMed ID: 33622884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Next generation sequencing in adult patients with glioblastoma in Switzerland: a multi-centre decision analysis.
    Zeitlberger AM; Putora PM; Hofer S; Schucht P; Migliorini D; Hottinger AF; Roelcke U; Läubli H; Spina P; Bozinov O; Weller M; Neidert MC; Hundsberger T
    J Neurooncol; 2022 Jul; 158(3):359-367. PubMed ID: 35486306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pediatric low-grade glioma in the era of molecular diagnostics.
    Ryall S; Tabori U; Hawkins C
    Acta Neuropathol Commun; 2020 Mar; 8(1):30. PubMed ID: 32164789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets.
    Sahm F; Schrimpf D; Jones DT; Meyer J; Kratz A; Reuss D; Capper D; Koelsche C; Korshunov A; Wiestler B; Buchhalter I; Milde T; Selt F; Sturm D; Kool M; Hummel M; Bewerunge-Hudler M; Mawrin C; Schüller U; Jungk C; Wick A; Witt O; Platten M; Herold-Mende C; Unterberg A; Pfister SM; Wick W; von Deimling A
    Acta Neuropathol; 2016 Jun; 131(6):903-10. PubMed ID: 26671409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mapping actionable pathways and mutations in brain tumours using targeted RNA next generation sequencing.
    Lenting K; van den Heuvel CNAM; van Ewijk A; ElMelik D; de Boer R; Tindall E; Wei G; Kusters B; Te Dorsthorst M; Ter Laan M; Huynen MA; Leenders WP
    Acta Neuropathol Commun; 2019 Nov; 7(1):185. PubMed ID: 31747973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metachronous, multicentric glioma of pilocytic astrocytoma with oligodendroglioma-like component and oligodendroglioma through distinct genetic aberrations.
    Kanoke A; Kanamori M; Kumabe T; Saito R; Watanabe M; Tominaga T
    J Neurosurg; 2013 Apr; 118(4):854-8. PubMed ID: 23082883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.